Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) COO Pad Chivukula Sells 12,000 Shares

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) COO Pad Chivukula sold 12,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $20.76, for a total transaction of $249,120.00. Following the sale, the chief operating officer now owns 435,334 shares of the company’s stock, valued at $9,037,533.84. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Arcturus Therapeutics Stock Performance

ARCT stock opened at $20.63 on Thursday. The stock has a market capitalization of $555.61 million, a PE ratio of -5.28 and a beta of 2.61. The company has a fifty day moving average of $21.06 and a 200-day moving average of $25.53. Arcturus Therapeutics Holdings Inc. has a one year low of $17.52 and a one year high of $45.00.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($0.64) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.85) by $1.21. The firm had revenue of $49.86 million for the quarter, compared to analyst estimates of $21.00 million. Arcturus Therapeutics had a negative return on equity of 25.47% and a negative net margin of 41.21%. During the same quarter in the prior year, the company posted ($1.98) earnings per share. Equities analysts forecast that Arcturus Therapeutics Holdings Inc. will post -2.6 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on ARCT shares. Leerink Partnrs raised shares of Arcturus Therapeutics to a “strong-buy” rating in a research report on Monday, August 12th. HC Wainwright reiterated a “buy” rating and issued a $63.00 price objective on shares of Arcturus Therapeutics in a research note on Tuesday, October 1st. Leerink Partners assumed coverage on shares of Arcturus Therapeutics in a research report on Monday, August 12th. They set an “outperform” rating and a $70.00 target price on the stock. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Arcturus Therapeutics in a research report on Monday, September 9th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $71.40.

Institutional Investors Weigh In On Arcturus Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Millennium Management LLC boosted its holdings in Arcturus Therapeutics by 250.1% during the second quarter. Millennium Management LLC now owns 555,024 shares of the biotechnology company’s stock worth $13,515,000 after buying an additional 396,505 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. boosted its position in Arcturus Therapeutics by 22.4% during the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,563,065 shares of the biotechnology company’s stock worth $38,061,000 after purchasing an additional 286,546 shares in the last quarter. ARK Investment Management LLC grew its holdings in Arcturus Therapeutics by 16.3% in the second quarter. ARK Investment Management LLC now owns 1,964,964 shares of the biotechnology company’s stock valued at $47,847,000 after purchasing an additional 275,315 shares during the last quarter. Nordea Investment Management AB purchased a new position in shares of Arcturus Therapeutics in the first quarter valued at $1,846,000. Finally, Jacobs Levy Equity Management Inc. increased its position in shares of Arcturus Therapeutics by 111.0% in the first quarter. Jacobs Levy Equity Management Inc. now owns 95,924 shares of the biotechnology company’s stock valued at $3,239,000 after buying an additional 50,470 shares in the last quarter. 94.54% of the stock is currently owned by hedge funds and other institutional investors.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.